- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00526383
Do Antidepressants Induce Metabolic Syndromes METADAP Study (METADAP)
Do Antidepressants Induce Metabolic Syndromes
Since antidepressants and antipsychotics have common receptorial mechanisms of action (H1 antagonism, 5HT2 antagonism), the impact of antidepressants in terms of metabolic syndromes is a matter of concern.
The main objective of this study is to assess the differential impact of antidepressants in terms of weight gain and metabolic syndromes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Since antidepressants and antipsychotics have common receptorial mechanisms of action (H1 antagonism, 5HT2 antagonism), the impact of antidepressants in terms of metabolic syndromes is a matter of concern.
The main objective of this study is to assess the differential impact of antidepressants in terms of weight gain and metabolic syndromes.
Prospective 6-month naturalistic cohort study, comparing 4 classes of antidepressants (SSRIs, SNRIs, TCAs and others) to a control group (ECT and r-TMS), in 600 patients with a major depressive disorder requiring the beginning of either antidepressant or ECT/r-TMS treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Assistance Publique hopital Bicêtre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age : 18-70
- Current major depressive episode (Major depressive disorder) based on the MINI interview
- HAM-D >18
- Requiring either antidepressant treatment, either ECT or r-TMS (as assessed by the clinician)
- Signed informed consent
Exclusion Criteria:
- Bipolar disorder (DSM-IV), Psychotic disorder (DSM-IV), Substance abuse or dependence (DSM-IV)
- Normothymic treatment
- Antipsychotic treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: B
|
antidepressant version medical dispositive
Other Names:
|
Experimental: A
antidepressant versus medical dispositive
|
antidepressant version medical dispositive
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Definition criteria of the metabolic syndromes: Weight and waist circumference Systolic and diastolic blood pressure Glycemia Triglyceridemia Cholesterolemia Insulinemia
Time Frame: at Months 0, 1, 3, 6
|
at Months 0, 1, 3, 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Antidepressant efficacy (HAM-D, quickIDS-C, quickIDS-SR, CGI)
Time Frame: at Months 0, 1, 3, 6
|
at Months 0, 1, 3, 6
|
Collaborators and Investigators
Investigators
- Principal Investigator: Emmanuelle CORRUBLE, MD PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
General Publications
- Chappell K, Ait Tayeb AEK, Colle R, Bouligand J, El-Asmar K, Gressier F, Trabado S, David DJ, Feve B, Becquemont L, Corruble E, Verstuyft C. The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients. Front Pharmacol. 2022 Oct 26;13:974570. doi: 10.3389/fphar.2022.974570. eCollection 2022.
- Chappell K, Colle R, Ait Tayeb AEK, Bouligand J, El-Asmar K, Deflesselle E, Feve B, Becquemont L, Corruble E, Verstuyft C. The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Dec 20;119:110608. doi: 10.1016/j.pnpbp.2022.110608. Epub 2022 Jul 22.
- Loeb E, Becquemont L, Corruble E. Is the decrease in NOx due to a lack of substrate or a NOS inhibition in patients with major depression? : Commentary on Hess et al. 2017. Psychopharmacology (Berl). 2021 Feb;238(2):613-614. doi: 10.1007/s00213-020-05747-x. Epub 2021 Jan 9. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P060219
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Tricyclic antidepressants
-
Tianjin Anding HospitalRecruitingHealthy | Anxiety DisorderChina
-
Xijing HospitalEnrolling by invitation
-
St. Louis UniversityCompletedDepression | Amyotrophic Lateral SclerosisUnited States
-
Danish Headache CenterCompletedTension-type HeadacheDenmark
-
The Third Affiliated hospital of Zhejiang Chinese...The Zhejiang Provincial Tongde Hospital; The Affiliated Hangzhou First People...Not yet recruiting
-
University of Sao PauloCompleted
-
Gerencia de Atención Primaria, AlbaceteUnknownDepression | Exercise | Primary CareSpain
-
Fundació Sant Joan de DéuUnknown
-
Tongji UniversityNot yet recruitingDepression | Pharmacogenomics
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited Arab Emirates, Singapore, Philippines, Austria, China, Hong Kong, Israel, Lebanon, Malaysia, Mexico, Saudi Arabia, Taiwan, Thailand